TGFB1 and cardiovascular disorder: Recently, the compound Si-Miao-Yong-An decoction (SMYAD), an inhibitor of the TGFβ1/Smad and TGFβ1/TAK1/p38 signaling pathways, was administered to TAC mice to assess its effects on cardiovascular disease development [66].